| ObjectiveBased on the chronic disease management platform of stroke of Guangdong Provincial Hospital of Traditional Chinese Medicine and the continuous management system of Chinese medicine prevention and treatment,retrospective analysis was used to observe the clinical efficacy of Dengzhan Shengmai Capsule in the treatment of patients with ischemic stroke and the impact of chronic disease management of stroke on secondary prevention of stroke during the treatment follow-up period.MethodsThis study was a retrospective study.From the chronic disease management system of Guangdong Provincial Hospital of Traditional Chinese Medicine,we searched for stroke recovery patients who were archived from January 2016 to December 2018.According to the inclusion criteria and exclusion criteria,the patients who were mainly treated by Western medicine were included in the control group.Patients treated with Dengzhan Shengmai Capsule based on the basic treatment of Western medicine were included in the observation group,and a total of 230 cases were screened out,115 cases in each of the observation group and the control group;All subjects had received chronic stroke management,including the establishment of chronic stroke management files.According to the cohort management plan of ischemic stroke recovery period,the patient was under comprehensive management of drugs,symptoms,high-risk factors,comorbidities/complications,lifestyle,mood,and establish long-term follow-up management,stroke health education management and core efficacy index evaluation,etc.Analyze and compare the Barthel index score,mRS scale score and Essen stroke scale score of the two groups of Patients at the time of filing,half a year of treatment and one year of treatment;Analyze the occurrence of end-point events of the two groups of patients after one year of treatment,including non-fatal stroke recurrence,number of deaths,cerebrovascular surgery,cardiovascular event incidence and peripheral arterial disease;The stroke awareness and chronic disease management compliance scale scores of the two groups of patients at the time of filing and one year after treatment were counted,and the differences in all data were analyzed using statistics.Results①There was no significant difference in age,gender,complications,mRS score,Barthel index score,and Essen stroke score at the time of filing between the two groups of patients(P>0.05),suggesting that the two groups of patients were comparable;②The mRS scores and Barthel index scores of the two groups of Patients during the six months and annual follow-up were significantly different than when they were established(P<0.05),but there was no significant difference between the groups(P>0.05),but one year after treatment,the disability rate of the observation group(7.8%)was significantly lower than that of the control group(13.0%);After one year of treatment,the proportion of the BI group in the observation group was slightly dependent(98.3%)than that in the control group(94.8%);there was no significant difference between the two groups of Patients after six months of treatment and one year in the Essen stroke scale score(P>0.05);③The number of stroke recurrences in the observation group after one year of treatment was 2 cases,accounting for 1.7%of the total number,and the number of cerebrovascular operations was 0 cases.The number of stroke recurrences in the control group after one year of treatment was 9 cases,accounting for 7.8%of the total number.The number of patients undergoing cerebrovascular surgery was 2 cases,and there was a significant difference in stroke recurrence rate between the two groups(P<0.05).There was no significant difference between the groups of patients undergoing cerebrovascular surgery(P>0.05).The mortality rate,the incidence of cardiovascular events and the number of peripheral arterial diseases were all 0;④The stroke awareness scores of the two groups of patients were increased before and after treatment and had significant differences(P<0.05),but there was no significant difference between the groups(P>0.05);The chronic disease management compliance scores of the two groups were elevated before and after treatment and had significant differences(P<0.05),and there was a significant difference between the groups(P<0.05),the mean compliance score of the observation group after treatment was higher than that of the control group;⑤During the treatment period,the two groups of Patients had withdrawals,and there was no significant difference between the groups(P>0.05),however,the number of discontinued drugs in the observation group(7)was less than that in the control group(10).ConclusionDengzhan Shengmai Capsule combined with Chinese medicine chronic disease management in the treatment of patients with ischemic stroke recovery period can significantly reduce the stroke recurrence rate;both treatment schemes can effectively improve the neurological dysfunction and improve the daily life ability of patients with stroke recovery period;On the basis of chronic disease management,Dengzhan Shengmai Capsule treatment has a tendency to improve the patient’s disability function(mRS score)and improve vitality(BI score)than simple western medicine basic treatment,and can increase the degree of independence of the patient’s life and reduce the occurrence of life dependence;Under the mode of chronic disease management,patients’ awareness of stroke-related knowledge has been significantly improved;Dengzhan Shengmai Capsule combined with chronic disease management can significant improves the compliance of patients taking medication on time,regular follow-up visits,diet management,exercise and control of risk factors,etc.This shows the advantages of Dengzhan Shengmai Capsule combined with chronic disease management in the secondary prevention of ischemic stroke. |
PDF Full Text Request